Zacks Investment Research on MSN
NTRA debuts Zenith Genomics next-gen sequencing test for rare diseases
Natera NTRA announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay designed to ...
Tuberculosis (TB) is the world’s leading cause of death from a single infectious agent, affecting more than 10 million people ...
The rapid evolution of HIV under antiretroviral pressure necessitates ongoing surveillance of drug resistance mutations. Next-generation sequencing (NGS) has emerged as a transformative technology in ...
Routine newborn screening (NBS) has transformed early disease detection. However, traditional biochemical tests limit the ...
Market Outlook and Growth TrajectoryThe global next generation sequencing market is poised to experience robust expansion, ...
Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...
Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic coverage Introducing two new high-throughput instrument configurations ...
Janina Krumbeck, PhD, discusses the clinical advantages of next-generation sequencing over traditional culture and how this ...
A new ultra-high-throughput sequencing platform boosts output, speeds turnaround, and improves genome coverage. It reduces ...
The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue to witness sequencer throughput expansion with systems like the Illumina ...
Dual-omic analysis to reveal gene regulatory network of immune landscape in childhood solid tumors and implications for immunotherapy. Phase 1/2 study of TSN222, a novel dual action tumor immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results